Abiomed Inc. (ABMD): Price and Financial Metrics
GET POWR RATINGS... FREE!
ABMD POWR Grades
- ABMD scores best on the Quality dimension, with a Quality rank ahead of 98.92% of US stocks.
- The strongest trend for ABMD is in Quality, which has been heading up over the past 26 weeks.
- ABMD ranks lowest in Value; there it ranks in the 14th percentile.
ABMD Stock Summary
- Price to trailing twelve month operating cash flow for ABMD is currently 67.9, higher than 94% of US stocks with positive operating cash flow.
- The ratio of debt to operating expenses for ABIOMED INC is higher than it is for about just 0.51% of US stocks.
- With a price/sales ratio of 15.87, ABIOMED INC has a higher such ratio than 93.47% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to ABIOMED INC, a group of peers worth examining would be HZNP, NTCT, AMSWA, CGNX, and PCTI.
- ABMD's SEC filings can be seen here. And to visit ABIOMED INC's official web site, go to www.abiomed.com.
ABMD Valuation Summary
- ABMD's price/sales ratio is 15.9; this is 695% higher than that of the median Healthcare stock.
- Over the past 243 months, ABMD's price/sales ratio has gone up 12.2.
Below are key valuation metrics over time for ABMD.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ABMD | 2022-12-05 | 15.9 | 11.1 | 63.9 | 49.5 |
| ABMD | 2022-12-02 | 15.8 | 11.0 | 63.8 | 49.3 |
| ABMD | 2022-12-01 | 15.8 | 11.1 | 63.8 | 49.4 |
| ABMD | 2022-11-30 | 15.9 | 11.1 | 63.9 | 49.4 |
| ABMD | 2022-11-29 | 15.8 | 11.0 | 63.8 | 49.3 |
| ABMD | 2022-11-28 | 15.8 | 11.0 | 63.8 | 49.3 |
ABMD Growth Metrics
- The year over year price growth rate now stands at -15.8%.
- The 4 year price growth rate now stands at 87.04%.
- Its 4 year revenue growth rate is now at 102.83%.
The table below shows ABMD's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 1,074.096 | 250.983 | 266.764 |
| 2022-06-30 | 1,056.317 | 298.134 | 217.584 |
| 2022-03-31 | 1,031.753 | 285.39 | 136.505 |
| 2021-12-31 | 1,003.148 | 292.893 | 133.036 |
| 2021-09-30 | 973.635 | 281.541 | 149.152 |
| 2021-06-30 | 935.257 | 298.178 | 154.412 |
ABMD's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ABMD has a Quality Grade of A, ranking ahead of 96.73% of graded US stocks.
- ABMD's asset turnover comes in at 0.659 -- ranking 58th of 186 Medical Equipment stocks.
- INGN, KIDS, and ATRC are the stocks whose asset turnover ratios are most correlated with ABMD.
The table below shows ABMD's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.659 | 0.819 | 0.206 |
| 2021-06-30 | 0.655 | 0.817 | 0.217 |
| 2021-03-31 | 0.616 | 0.809 | 0.303 |
| 2020-12-31 | 0.623 | 0.809 | 0.278 |
| 2020-09-30 | 0.643 | 0.808 | 0.303 |
| 2020-06-30 | 0.667 | 0.812 | 0.248 |
ABMD Price Target
For more insight on analysts targets of ABMD, see our ABMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $387.33 | Average Broker Recommendation | 1.65 (Moderate Buy) |
ABMD Stock Price Chart Interactive Chart >
ABMD Price/Volume Stats
| Current price | $380.75 | 52-week high | $381.99 |
| Prev. close | $377.79 | 52-week low | $219.85 |
| Day low | $380.25 | Volume | 1,506,800 |
| Day high | $381.80 | Avg. volume | 485,853 |
| 50-day MA | $320.96 | Dividend yield | N/A |
| 200-day MA | $287.99 | Market Cap | 17.17B |
Abiomed Inc. (ABMD) Company Bio
Abiomed is a publicly-traded medical device technology company that develops and manufactures temporary external and implantable mechanical circulatory support devices. The company is headquartered in Danvers, Massachusetts with additional offices in Woburn, Baltimore, Berlin, Aachen, and Tokyo. Michael R. Minogue is Chairman, CEO & President of the company, with Dr. Thorsten Siess as Chief Technology Officer and Dr. Chuck Simonton as Chief Medical Officer. According to Bloomberg, the company "engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients". As of 2022, the company had secured five FDA approvals and 1,408 patents with 1,416 pending. For fiscal year 2022, Abiomed reported $1.032 billion in revenue and reported diluted earnings per share was $2.98 for the year. (Source:Wikipedia)
Latest ABMD News From Around the Web
Below are the latest news stories about ABIOMED INC that investors may wish to consider to help them evaluate ABMD as an investment opportunity.
First Patients in the World Treated with Impella RP Flex with SmartAssistDANVERS, Mass., December 05, 2022--Abiomed announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist. |
Why Is Abiomed (ABMD) Up 1.2% Since Last Earnings Report?Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Eleven Stocks Turned $10,000 To $261,421 In 11 MonthsMost S&P 500 investors got a little gain this month. But investors willing to look off the beaten path found huge gains. |
Here's Why You Should Hold on to Abiomed (ABMD) Stock NowInvestors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line. |
Here''s How Much You Would Have Made Owning Abiomed Stock In The Last 15 YearsAbiomed (NASDAQ: ABMD ) has outperformed the market over the past 15 years by 18.87% on an annualized basis producing an average annual return of 25.88%. Currently, Abiomed has a market capitalization of $17.04 billion. Buying $1000 In ABMD: If an … Full story available on Benzinga.com |
ABMD Price Returns
| 1-mo | 1.80% |
| 3-mo | 34.88% |
| 6-mo | 52.04% |
| 1-year | 21.96% |
| 3-year | 111.82% |
| 5-year | 98.97% |
| YTD | 6.01% |
| 2021 | 10.79% |
| 2020 | 90.05% |
| 2019 | -47.52% |
| 2018 | 73.44% |
| 2017 | 66.32% |
Continue Researching ABMD
Here are a few links from around the web to help you further your research on Abiomed Inc's stock as an investment opportunity:Abiomed Inc (ABMD) Stock Price | Nasdaq
Abiomed Inc (ABMD) Stock Quote, History and News - Yahoo Finance
Abiomed Inc (ABMD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...